Breaking News, Financial News

BioNTech Revenues Slide with Waning Demand for COVID-19 Vaccines

Approximately 2 billion doses of COMIRNATY invoiced in 2022, including approximately 550 million doses of Omicron-adapted bivalent COVID-19 vaccines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech 4Q Revenues: €4.3 billion (-23%) 4Q Earnings: €2.3 billion (-28%) YTD Revenues: €17.3 billion (-9%) YTD Earnings: €9.3 billion (-8%) Comments: Results in the quarter and FY reflect lower demand for COVID-19 vaccines. Approximately 2 billion doses of COMIRNATY invoiced in 2022, including approximately 550 million doses of Omicron-adapted bivalent COVID-19 vaccines.   BioNTech expanded its oncology pipeline to 20 programs with 24 ongoing clinical trials including five Phase 2 clini...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters